A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
Christophe Massard, Jean‐Charles Soria, Alan Anthoney, Alicia M Proctor, Angela Scaburri, M. A. Pacciarini, B. Laffranchi, Cinzia Pellizzoni, Guido Guido Kroemer, Jean‐Pierre Armand, Rastilav Balheda, Christopher Twelves (2011). A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors. , 10(6), DOI: https://doi.org/10.4161/cc.10.6.15075.
